These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10508045)

  • 41. Does Critical Illness Change Levofloxacin Pharmacokinetics?
    Roberts JA; Cotta MO; Cojutti P; Lugano M; Della Rocca G; Pea F
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1459-63. PubMed ID: 26666946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.
    Malone RS; Fish DN; Abraham E; Teitelbaum I
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3148-55. PubMed ID: 11600370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
    Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients.
    Ikawa K; Morikawa N; Hayato S; Ikeda K; Ohge H; Sueda T
    Int J Antimicrob Agents; 2007 Sep; 30(3):270-3. PubMed ID: 17587550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Relationship between PK/PD of Cefepime and Clinical Outcome in Febrile Neutropenic Patients with Normal Renal Function].
    Yamashita Y; Kamiyama H; Yamamoto A; Kanoh H; Yuhki Y; Ueda A; Kawamoto Y; Gotoh Y; Yamamoto S
    Yakugaku Zasshi; 2016; 136(12):1641-1649. PubMed ID: 27904098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cefepime dosing in the morbidly obese patient population.
    Rich BS; Keel R; Ho VP; Turbendian H; Afaneh CI; Dakin GF; Pomp A; Nicolau DP; Barie PS
    Obes Surg; 2012 Mar; 22(3):465-71. PubMed ID: 22249886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
    Oliver WD; Heil EL; Gonzales JP; Mehrotra S; Robinett K; Saleeb P; Nicolau DP
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1899-901. PubMed ID: 26711770
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.
    Rhodes NJ; Kuti JL; Nicolau DP; Neely MN; Nicasio AM; Scheetz MH
    J Infect Chemother; 2016 Feb; 22(2):78-83. PubMed ID: 26712584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.
    König C; Braune S; Roberts JA; Nierhaus A; Steinmetz OM; Baehr M; Frey OR; Langebrake C; Kluge S
    J Antimicrob Chemother; 2017 May; 72(5):1433-1440. PubMed ID: 28175308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.
    Huwyler T; Lenggenhager L; Abbas M; Ing Lorenzini K; Hughes S; Huttner B; Karmime A; Uçkay I; von Dach E; Lescuyer P; Harbarth S; Huttner A
    Clin Microbiol Infect; 2017 Jul; 23(7):454-459. PubMed ID: 28111294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cefepime versus cefpirome: the importance of creatinine clearance.
    Lipman J; Wallis SC; Boots RJ
    Anesth Analg; 2003 Oct; 97(4):1149-1154. PubMed ID: 14500173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
    Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stability and antibacterial activity of cefepime during continuous infusion.
    Sprauten PF; Beringer PM; Louie SG; Synold TW; Gill MA
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1991-4. PubMed ID: 12760882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.